尊龙凯时·(中国区)人生就是搏!

2016年第3期《药学进展》:21世纪2型糖尿病新药研发策略:明鉴病理因素,改善机体功能

药学进展
尊龙凯时医药
Oct 01, 2016
5380

Online link unavailable, presentationavailable upon request. (BD@wzjhad.com)

Next Page:
2016 May / Drug Design, Development and Therapy: Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study
Focus Us
Copyright © 2024  Hua Medicine (Shanghai) Co., Ltd.    互联网药品信息服务资格证书编号: (沪)-非经营-2022-0079
沪ICP备14036654号-1  beiantubiao.png 沪公网安备 31011502013809号  Privacy Statement  Terms of Use
Search
How we use cookies
Hua Medicine uses cookies to enable and improve the use of the website. By continuing to use the site, you consent to the use of these cookies. To learn more about cookies, please read our privacy statement.
Accept
x
友情链接: